Medical AI

With a promise of cellular renewal via exosomes, (plated) Skin Science is leading a biotech revolution. But can it navigate the hype and regulatory hurdles?

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

Neuroscientist-founded Steffie's launches wide-fit heels, blending sneaker tech with style to solve a problem millions of women face. Is this the future?

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

A new partnership model merges virtual nephrology, clinical trials, and real-world data, aiming to empower independent doctors and improve patient access.

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

UCLA's Dr. Donald Kohn joins the Jeffrey Modell Foundation to discuss revolutionary gene therapies offering new hope for Primary Immunodeficiency patients.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

Wolters Kluwer's UpToDate again tops KLAS rankings, highlighting a major trend: integrating expert-backed patient education directly into clinical care.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

A novel cell therapy for Parkinson's earns a key FDA designation, signaling a potential paradigm shift from managing symptoms to reversing the disease.

Equinox's new EQX ARC program partners with Oura and Function to offer hyper-personalized, data-driven training for women across all life stages.

For the 24th straight year, nurses top Gallup's ethics poll, but this enduring trust masks a profession in crisis, battling burnout and staff shortages.

With $82M in funding and novel gene insertion technology, Averna Therapeutics is poised to make waves at the pivotal J.P. Morgan Healthcare Conference.

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

Dr. Timothy Lubenow's move from a top university to a community clinic highlights a trend that's making advanced medical care more accessible.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.